Nautilus Biotechnology Inc. stocks have been trading up by 12.79 percent following highly positive sentiment around its latest technological advances.
Click Here for a Millionaire's POV on Trading NAUT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Roth Capital started coverage on Nautilus Biotechnology with a Buy rating and a $3.50 price target, highlighting upside tied to its AI-powered Voyager proteomics platform.
- The new Wall Street coverage signals a constructive view on NAUT’s valuation as the company pushes deeper into oncology, neurology, and broader therapeutic markets.
- NAUT shares have ripped from under $1.00 to above $2.30 in weeks, showing strong momentum that active traders are now tracking closely.
- Wide intraday swings around $2.50 underline NAUT as a volatile momentum play, not a sleepy biotech grinder.
Live Update At 12:32:44 EDT: On Monday, October 19, 2026 Nautilus Biotechnology Inc. stock [NASDAQ: NAUT] is trending up by 12.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Nautilus Biotechnology Inc. sits in classic early-stage biotech territory: tiny revenue, heavy research burn, and a balance sheet built to fund long development cycles. In the latest quarter, NAUT posted just $10,000 in total revenue while logging about $9.6M in research expense and $6.3M in general and administrative costs. That pushed quarterly net loss to roughly $14.5M, or about -$0.11 per share.
For traders, the key is runway. NAUT reported about $84.0M in cash, cash equivalents, and short-term investments, with working capital near $79.0M and a current ratio over 10. That’s a big liquidity cushion relative to quarterly operating cash outflow of about $13.7M. NAUT also carries modest leverage, with long-term debt around $23.8M against $131.1M in equity.
More Breaking News
- Cleveland-Cliffs Stock Draws Upgrades As Grid Steel Bet Expands
- RTX Stock Strengthens As Mega Defense Wins Pile Up
- IRON Stock Jumps As Traders Position For APOLLO Readout
- CoreWeave (CRWV) Stock Turns Volatile As Debt Fears Clash With AI Expansion
On valuation, NAUT trades at a rich price-to-sales multiple above 1,500x because revenue is still almost zero. The real story is optionality: traders are paying up today for potential future traction of its AI-driven Voyager proteomics platform, not current income. That gap between story and numbers is exactly where momentum and volatility live.
Why Traders Are Watching NAUT After Roth’s Buy Call
NAUT has turned from a sleepy sub-$1.00 biotech into a two-handle momentum name in a matter of weeks. At the end of 2026/09, Nautilus Biotechnology was closing near $0.96–$1.11. By 2026/10/19, NAUT closed at $2.325 after hitting an intraday high of $2.50. That’s more than a double off the late-September base and a clear trend shift that chart-focused traders notice.
The catalyst: Roth Capital stepped in with fresh coverage, slapping a Buy rating and a $3.50 price target on Nautilus Biotechnology. That target sits well above the current $2s, signaling that at least one Wall Street shop believes NAUT’s AI-powered Voyager platform has real upside in oncology, neurology, and other therapeutic areas. For story-driven biotech trading, that kind of external validation matters.
Intraday action backs up the narrative. On the latest session, NAUT opened near $2.03, dipped to $1.97, then ran to $2.50 before settling in the low $2.30s. The 5‑minute chart shows a steady grind from the low $2.00s in the morning into a midday spike near $2.49, followed by controlled consolidation above $2.30. Nautilus Biotechnology is trading like a momentum breakout, not a random pop.
For short-term traders, the $2.00 area now looks like a key psychological pivot, with the $2.50 intraday high and Roth’s $3.50 target forming a clear upside ladder. As long as NAUT holds higher lows on pullbacks, many momentum traders will keep it on watch for follow-through.
Conclusion
Nautilus Biotechnology and ticker NAUT are now firmly on the radar of active small-cap biotech traders. The company is still pre-commercial in any meaningful sense, burning cash to build out its Voyager proteomics platform, with margins and returns deep in the red. But the balance sheet is solid for now, and Wall Street is starting to weigh in.
Roth Capital’s Buy rating and $3.50 price target tell traders that at least one firm believes NAUT’s current valuation leaves room for upside, especially if AI-powered proteomics wins share in high-value areas like oncology and neurology. That narrative, combined with a strong run from under $1.00 to the mid-$2s, turns Nautilus Biotechnology into a classic speculation vehicle.
For disciplined traders, NAUT is less about believing the long-term biotech dream and more about respecting the chart, respecting the range, and respecting the risk. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. As Tim Sykes likes to say, “The pattern matters more than the promise — trade the price action, not the hype.” Nautilus Biotechnology now has both a story and a signal; how traders handle that mix will decide who wins and who gets chopped up chasing.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.